Last reviewed · How we verify

Pocket Naloxone Corp — Portfolio Competitive Intelligence Brief

Pocket Naloxone Corp pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Naloxone Nasal Spray Naloxone Nasal Spray phase 3 Opioid receptor antagonist Mu opioid receptor (primary); delta and kappa opioid receptors Emergency Medicine / Toxicology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Albert Einstein Healthcare Network · 1 shared drug class
  2. Cephalon · 1 shared drug class
  3. Leiden University Medical Center · 1 shared drug class
  4. New York State Psychiatric Institute · 1 shared drug class
  5. Paion UK Ltd. · 1 shared drug class
  6. State University of New York - Upstate Medical University · 1 shared drug class
  7. Texas Tech University · 1 shared drug class
  8. The Scripps Research Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Pocket Naloxone Corp:

Cite this brief

Drug Landscape (2026). Pocket Naloxone Corp — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pocket-naloxone-corp. Accessed 2026-05-16.

Related